Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis

Cancer Biomarkers

Volumn 17, Issue 1, 2016, Pages 55-65

  Rychlíková, Jana ^a   Vecka, Marek ^a   Jáchymová, Marie ^b   Macášek, Jaroslav ^a   Hrabák, Petr ^a   Zeman, Miroslav ^a   Vávrová, Lucie ^a   Řoupal, Jan ^b   Krechler, Tomáš ^a   Ák, Aleš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

chronic non hereditary pancreatitis; Osteopontin; pancreatic ductal adenocarcinoma; type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C PEPTIDE; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; OSTEOPONTIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; TUMOR MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CANCER PATIENT; CANCER STAGING; CHOLESTEROL BLOOD LEVEL; CHRONIC NON HEREDITARY PANCREATITIS; CHRONIC PANCREATITIS; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; BLOOD; CARCINOMA, PANCREATIC DUCTAL; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; DIFFERENTIAL DIAGNOSIS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC;

AGED; BIOMARKERS; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC;

EID: 84978518645     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-160617     Document Type: Article

References (81)

1. M. Ahmed, G.C. Kundu, Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Mol Cancer 9 (2010), 101.
2. M. Ahmed, R. Behera, G. Chakraborty, S. Jain, V. Kumar, P. Sharma, A. Bulbule, S. Kale, S. Kumar, R. Mishra, R. Raja, S. Saraswati, R. Kaur, G. Soundararajan, D. Kumar, D. Thorat, M. Sanyal, A. Ramdasi, P. Ghosh, G.C. Kundu, Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 15 (2011), 1113-1126.
3. D. Agrawal, T. Chen, R. Irby, J. Quackenbush, A.F. Chambers, M. Szabo, A. Cantor, D. Coppola, T.J. Yeatman, Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling, J Natl Cancer Inst 94 (2002), 513-521.
4. U.K. Ballehaninna, R.S. Chamberlain, Biomarkers for pancreatic cancer: promising new markers, and options beyond CA 19-9. Tumor Biol 34 (2013), 3279-3292.
5. A.E. Berezin, A.A. Kremzer, Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease, Atherosclerosis 229 (2013), 475-481.
6. A. Berrington de Gonzalez, S. Sweetland, E. Spencer, Ametaanalysis of obesity, and the risk of pancreatic cancer. Br J Cancer 89 (2003), 519-523.
7. G. Bertino, A. Ardiri, M. Malaguarnera, G. Malaguarnera, N. Bertino, G.S. Calvagno, Hepatocellualar carcinoma serum markers, Semin Oncol 39 (2012), 410-433.
8. W. Blogowski, K. Dolegowska, A. Deskur, B. Dolegowska, T. Starzýnska, An Attempt to Evaluate Selected Aspects of Bone-Fat Axis Function in Healthy Individuals, and Patients With Pancreatic Cancer, Medicine (Baltimore) 94 (2015), e1303.
9. R.E. Brand, B.M. Nolen, H.J. Zeh, P.J. Allen, M.A. Eloubeidi, M. Goldberg, E. Elton, J.P. Arnoletti, J.D. Christein, S.M. Vickers, C.J. Langmead, D.P. Landsittel, D.C. Whitcomb, W.E. Grizzle, A.E. Lokshin, Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 17 (2010), 805-816.
10. D.A. Brott, S.T. Furlong, S.H. Adler, J.W. Hainer, R.B. Arani, M. Pinches, P. Rossing, N. Chaturvedi, DIRECT programme steering committee, characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing, and qualification using samples from subjects with diabetes, Drug Des Devel Ther 9 (2015), 3191-3198.
11. A.F. Chambers, S.M. Wilson, N. Kerkvliet, F.P. O?Malley, J.F. Harris, A.G. Casson, Osteopontin expression in lung cancer. Lung Cancer 15 (1996), 311-323.
12. J. Chen, K. Singh, B.B. Mukherjee, J. Sodek, Developmental expression of osteopontin (OPN) mRNA in rat tissues: evidence for a role for OPN in bone formation, and resorption. Matrix 13 (1993), 113-123.
13. R. Chen, D.A. Crispin, S. Pan, S. Hawley, M.W. McIntosh, D. May, H. Anton-Culver, A. Ziogas, M.P. Bronner, T.A. Brentnall, Pilot study of blood biomarker candidates for detection of pancreatic cancer. Pancreas 39 (2010), 981-988.
14. A.L. Collins, J. Rock, L. Malhotra, W.L. Frankel, M. Bloomston, Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma. Ann Surg Oncol 19 (2012), 2673-2678.
15. D. Coppola, M. Szabo, D. Boulware, P. Muraca, M. Alsarraj, A.F. Chambers, T.J. Yeatman, Correlation of osteopontin protein expression, and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10 (2004), 184-190.
16. M. Dalamaga, K.N. Diakopoulos, C.S. Mantzoros, The role of adiponectin in cancer: a review of current evidence, Endocr Rev 33 (2012), 547-594.
17. G. Daniele, R. Guardado Mendoza, D. Winnier, T.V. Fiorentino, Z. Pengou, J. Cornell, F. Andreozzi, C. Jenkinson, E. Cersosimo, M. Federici, D. Tripathy, F. Folli, The inflammatory status score including IL-6, TNF-a, osteopontin, fractalkine, MCP-1, and adiponectin underlies whole-body insulin resistance, and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51 (2014), 123-131.
18. J. Everhart, D. Wright. Diabetes mellitus as a risk factor for pancreatic cancer, A meta-Analysis. JAMA 273 (1995), 1605-1609.
19. N.S. Fedarko, A. Jain, A. Karadag, M.R. Van Eman, L.W. Fisher, Elevated serum bone sialoprotein, and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7 (2001), 4060-4066.
20. R. Freelove, A.D. Walling, Pancreatic cancer: diagnosis, and management. Am Fam Phys 73 (2006), 485-492.
21. C.S. Fuchs, G.A. Colditz, M.J. Stampfer, E.L. Giovannucci, D.J. Hunter, E.B. Rimm, W.C. Willett, F.E. Speizer, A prospective study of cigarette smoking, and the risk of pancreatic cancer. Arch Intern Med 156 (1996), 2255-2260.
22. N. Fukushima, J. Koopmann, N. Sato, N. Prasad, R. Carvalho, S.D. Leach, R.H. Hruban, M. Goggins, Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mol Pathol 18 (2005), 779-787.
23. S. Genuth, K.G. Alberti, P. Bennett, J. Buse, R. Defronzo, R. Kahn, J. Kitzmiller, W.C. Knowler, H. Lebovitz, A. Lernmark, D. Nathan, J. Palmer, R. Rizza, C. Saudek, J. Shaw, M. Steffes, M. Stern, J. Tuomilehto, P. Zimmet. Expert Committee on the Diagnosis, and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 (2003), 3160-3167.
24. C.M. Giachelli, N. Bae, M. Almeida, D.T. Denhardt, C.E. Alpers, S.M. Schwartz, Osteopontin is elevated during neointima formation in rat arteries, and is a novel component of human atherosclerotic plaques. J Clin Invest 92 (1993), 1686-1696.
25. M. Gotoh, M. Sakamoto, K. Kanetaka, M. Chuuma, S. Hirohashi, Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 52 (2002), 19-24.
26. F.L. Greene, D.L. Page, I.D. Fleming, A. Fritz, C.M. Balch, D.G. Haller, M. Morrow, eds, AJCC cancer staging manual, 6th ed, New York Springer-Verlag, (2002
27. R.J. Jansen, X.L. Tan, G.M. Petersen, Gene-by-environment interactions in pancreatic cancer: implications for prevention. Yale J Biol Med 88 (2015), 115-126.
28. F. Kaleaǧasioǧlu, M.R. Berger, SIBLINGs, and SPARC families: their emerging roles in pancreatic cancer. World J Gastroenterol 20 (2014), 14747-14759.
29. J.H. Kim, S.J. Skates, T. Uede, K.K. Wong, J.O. Schorge, C.M. Feltmate, R.S. Berkowitz, D.W. Cramer, S.C. Mok, Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287 (2002), 1671-1679.
30. J. Kodydkova, L. Vavrova, B. Stankova, J. Macasek, T. Krechler, A. Zak, Antioxidant status, and oxidative stress markers in pancreatic cancer, and chronic pancreatitis. Pancreas 42 (2013), 614-621.
31. A. Kolb, J. Kleeff, A. Guweidhi, I. Esposito, N.A. Giese, H. Adwan, T. Giese, M.W. Büchler, M.R. Berger, H. Friess, Osteopontin influences the invasiveness of pancreatic cancer cells, and is increased in neoplastic, and inflammatory conditions. Cancer Biol Ther 4 (2005), 740-746.
32. L. Konieczna, J. Skokowski, I. Oledzka, K. Macur, M. Belka, T. Baczek, W. Struck, M. Markuszewski, The osteopontin tissue level as a breast cancer biomarker in females after mastectomy measured by the capillary gel electrophoresis technique, Comb Chem High Throughput Screen 16 (2013), 331-338.
33. J. Koopmann, N.S. Fedarko, A. Jain, A. Maitra, C. Iacobuzio-Donahue, A. Rahman, R.H. Hruban, C.J. Yeo, M. Goggins, Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 13 (2004), 487-491.
34. J. Koopmann, N.W. Rosenzweig, Z. Zhang, M.I. Canto, D.A. Brown, M. Hunter, C. Yeo, D.W. Chan, S.N. Breit, M. Goggins, Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12 (2006), 442-446.
35. T. Krechler, M. Jachymova, M. Pavlikova, M. Vecka, M. Zeman, Z. Krska, T. Svestka, A. Zak, Polymorphism-23HPhI in the promoter of insulin gene, and pancreatic cancer: a pilot study. Neoplasma 56 (2009), 26-32.
36. T. Krechler, M. Zeman, M. Vecka, J. Macasek, M. Jachymova, T. Zima, A. Zak, Leptin, and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma 58 (2011), 58-64.
37. N. Kuno, K. Kurimoto, M. Fukushima, T. Hayakawa, T. Shibata, T. Suzuki, A. Sakakibara, N. Katada, S. Nakano, T. Takayama, et al., Effectiveness of multivariate analysis of tumor markers in diagnosis of pancreatic carcinoma: a propective study in multiinstitutions. Pancreas 9 (1994), 725-730.
38. M. Lazar, J. Sullivan, G. Chipitsyna, Q. Gong, C.Y. Ng, A.F. Salem, T. Aziz, A. Witkiewicz, D.T. Denhardt, C.J. Yeo, H.A. Arafat, Involvement of osteopontin in the matrix-degrading, and proangiogenic changes mediated by nicotine in pancreatic cancer cells, J Gastrointest Surg, DOI 101007/s11605-010-1338-0.
39. Q.T. Le, P.D. Sutphin, S. Raychaudhuri, S.C. Yu, D.J. Terris, H.S. Lin, B. Lum, H.A. Pinto, A.C. Koong, A.J. Giaccia, Identification of osteopontin as a prognostic plasma marker for head, and neck squamous cell carcinomas. Clin Cancer Res 9 (2003), 59-67.
40. J.-J. Li, H.-Y. Li, F. Gu, Diagnostic significance of serum osteopontin level for pancreatic cancer: a meta analysis, Gent Test Mol Biomarkers 18(8) (2014), 580-586.
41. Y. Lin, K. Yagyu, N. Egawa, M. Ueno, M. Mori, H. Nakao, H. Ishii, K. Nakamura, K. Wakai, S. Hosono, A. Tamakoshi, S. Kikuchi, An overview of genetic polymorphisms, and pancreatic cancer risk in molecular epidemiologic studies. J Epidemiol 21 (2011), 2-12.
42. J. Louhimo, H. Alfthan, U.H. Stenman, C. Haglund, Serum HCG beta, and CA 72-4 are stronger prognostic factors than CEA, CA 19-9, and CA 242 in pancreatic cancer. Oncology 66 (2004), 126-131.
43. S.A. Lund, C.M. Giachelli, M. Scatena, The role of osteopontin in inflammatory processes. J Cell Commun Signal 3 (2009), 311-322.
44. G. Marsche, M.D. Saemann, A. Heinemann, M. Holzer, In flammation alters HDL composition, and function: implications for HDL-raising therapies. Pharmacol Ther 137 (2013), 341-351.
45. K. Matusan-Ilijas, S. Behrem, N. Jonjic, K. Zarkovic, K. Lucin, Osteopontin expression correlates with angiogenesis, and survival in malignant astrocytoma. Pathol Oncol Res 14 (2008), 293-298.
46. T. Nakamachi, T. Nomiyama, F. Gizard, E.B. Heywood, K.L. Jones, Y. Zhao, L. Fuentes, K. Takebayashi, Y. Aso, B. Staels, T. Inukai, D. Bruemmer, PPARalpha agonists suppress osteopontin expression in macrophages, and decrease plasma levels in patients with type 2 diabetes. Diabetes 56 (2007), 1662-1670.
47. M. Nakamura, M. Oka, N. Iizuka, S. Kawauchi, T. Gondo, T. Ueno, A. Tangoku, Osteopontin expression in chronic pancreatitis. Pancreas 25 (2002), 182-187.
48. B.M. Nolen, R.E. Brand, D. Prosser, L. Velikokhatnaya, P.J. Allen, H.J. Zeh, W.E. Grizzle, A. Lomakin, A.E. Lokshin, Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. PLoS ONE 9(4) (2014), e94928. doi: 101371/journal. pone.0094928.
49. S.N. Osayi, M. Bloomston, C.M. Schmidt, E.C. Ellison, P. Muscarella, Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: a review. Biomed Res Int 2014 (2014), 468959.
50. H.W. Pan, Y.H. Ou, S.Y. Peng, S.H. Liu, P.L. Lai, P.H. Lee, J.C. Sheu, C.L. Chen, H.C. Hsu, Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98 (2003), 119-127.
51. R. Patarca, R.A. Saavedra, H. Cantor, Molecular, and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol 13 (1993), 225-246.
52. K.E. Poruk, M.A. Firpo, C.L. Scaife, D.G. Adler, L.L. Emerson, K.M. Boucher, S.J. Mulvihill, Serum osteopontin, and tissue inhibitor of metalloproteinase 1 as diagnostic, and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 42 (2013), 193-197.
53. A. Riker, S.K. Libutti, D.L. Bartlets, Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol 6 (1997), 157-169.
54. K. Sarosiek, E. Jones, G. Chipitsyna, M. Al-Zoubi, C. Kang, S. Saxena, A.V. Gandhi, J. Sendiky, C.J. Yeo, H.A. Arafat, Osteopontin (OPN) isoforms. Diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN. J Gastrointest Surg 19 (2015), 639-650.
55. S. Saxena, A. Gandhi, P.W. Lim, D. Relles, K. Sarosiek, C. Kang, G. Chipitsyna, J. Sendecki, C.J. Yeo, H.A. Arafat, RAN GTPase, and Osteopontin in Pancreatic Cancer. Pancreat Disord Ther 3 (2013), 113.
56. A. Schneider, J.M. Löhr, M.V. Winter, The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classification of the disease. J Gastroenterol 42 (2007), 101-119.
57. D.R. Senger, C.A. Perruzzi, A. Papadopoulos, Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9 (1989), 1291-1299.
58. S. Shang, A. Plymoth, S. Ge, Z. Feng, H.R. Rosen, S. Sangrajrang, P. Hainaut, J.A. Marrero, L. Beretta, Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 55 (2012), 483-490.
59. N. Shijubo, T. Uede, S. Kon, M. Maeda, T. Segawa, A. Imada, M. Hirasawa, S. Abe, Vascular endothelial growth factor, and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160 (1999), 1269-1273.
60. A.A. Siddiqui, E. Jones, D. Andrade, A. Shah, T.E. Kowalski, D.E. Loren, G. Chipitsyna, H.A. Arafat, Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma. J Gastroenterol Hepatol 29 (2014), 1321-1327.
61. H. Singhal, D.S. Bautista, K.S. Tonkin, F.P. O?Malley, A.B. Tuck, A.F. Chambers, J.F. Harris, Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden, and decreased survival. Clin Cancer Res 3 (1997), 605-611.
62. C. Sodhi, S.A. Phadke, D. Batlle, A. Sahai, Hypoxia, and high glucose cause exaggerated mesangial cell growth, and collagen synthesis: role of osteopontin. Am J Physiol Renal Surgery 146 (2009), 232-240.
63. J. Sullivan, L. Blair, A. Alnajar, T. Aziz, C.Y. Ng, G. Chipitsyna, Q. Gong, A. Witkiewicz, G.F. Weber, D.T. Denhardt, C.J. Yeo, H.A. Arafat, Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Physiol 280 (2009), F667-F674.
64. H. Takada, T. Nakazawa, H. Ohara, T. Ando, K. Hayashi, I. Naito, F. Okumura, H. Tanaka, T. Yamada, S. Takahashi, T. Joh, Role of osteopontin in calcification in autoimmune pancreatitis. Dig Dis Sci 54 (2009), 793-801.
65. M. Takemoto, K. Yokote, M. Nishimura, T. Shigematsu, T. Hasegawa, S. Kon, T. Uede, T. Matsumoto, Y. Saito, S. Mori, Enhanced expression of osteopontin in human diabetic artery, and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol 20 (2000), 624-628.
66. G.N. Thalmann, R.A. Sikes, R.E. Devoll, J.A. Kiefer, R. Markwalder, I. Klima, C.M. Farach-Carson, U.E. Studer, L.W. Chung, Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5 (1999), 2271-2277.
67. J.W. Thoms, A. Dal Pra, P.H. Anborgh, E. Christensen, N. Fleshner, C. Menard, K. Chadwick, M. Milosevic, C. Catton, M. Pintilie, A.F. Chambers, R.G. Bristow, Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category, and treatment response. Br J Cancer 107 (2012), 840-846.
68. A.B. Tuck, F.P. O?Malley, H. Singhal, K.S. Tonkin, J.F. Harris, D. Bautista, A.F. Chambers, Osteopontin, and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121 (1997), 578-584.
69. A.B. Tuck, F.P. O?Malley, H. Singhal, J.F. Harris, K.S. Tonkin, N. Kerkvliet, Z. Saad, G.S. Doig, A.F. Chambers, Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79 (1998), 502-508.
70. A.B. Tuck, D.M. Arsenault, F.P. O?Malley, C. Hota, M.C. Ling, S.M. Wilson, A.F. Chambers, Osteopontin induces increased invasiveness, and plasminogen activator expression of human mammary epithelial cells. Oncogene 18 (1999), 4237-4246.
71. A.B. Tuck, A.F. Chambers, A.L. Allan, Osteopontin overexpression in breast cancer: knowledge gained, and possible implications for clinical management. J Cell Biochem 102 (2007), 859-868.
72. T. Ue, H. Yokozaki, Y. Kitadai, S. Yamamoto, W. Yasui, T. Ishikawa, E. Tahara, Co-expression of osteopontin, and CD44v9 in gastric cancer. Int J Cancer 79 (1998), 127-132.
73. S. Yachida, S. Jones, I. Bozic, T. Antal, R. Leary, et al., Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 (2010), 1114-1117.
74. H. Yamaguchi, M. Igarashi, A. Hirata, H. Tsuchiya, K. Sugiyama, Y. Morita, Y. Jimbu, H. Ohnuma, M. Daimon, M. Tominaga, T. Kato, Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J 51 (2004), 499-504.
75. X. Yan, M. Sano, L. Lu, W. Wang, Q. Zhang, R. Zhang, L. Wang, Q. Chen, K. Fukuda, W. Shen, Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence, and severity of nephropathy, and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 9 (2010), 70.
76. L. Vavrova, J. Rychlikova, M. Mrackova, O. Novakova, A. Zak, F. Novak, Increased inflammatory markers with altered antioxidant status persist after clinical recovery from severe sepsis: a correlation with low HDL cholesterol, and albumin. Clin Exp Med (Sep 28 2015). [Epub ahead of print].
77. E.M. Vestergaard, H.O. Hein, H. Meyer, N. Grunnet, J. Jørgensen, H. Wolf, T.F. ørntoft, Reference values, and biological variation for tumor marker CA 19-9 in serum for different lewis, and secretor genotypes, and evaluation of secretor, and lewis genotyping in a caucasian population. Clin Chem 45 (1999), 54-61.
78. P.Y. Wai, P.C. Kuo, The role of osteopontin in tumor metastasis. J Surg Res 121 (2004), 228-241.
79. G.F. Weber, S. Ashkar, M.J. Glimcher, H. Cantor, Receptorligand interaction between CD44, and osteopontin (Eta-1). Science 271 (1996), 509-512.
80. G.F. Weber, The metastasis gene osteopontin: a candidate target for cancer therapy, Biochim Biophys Acta 1552 (2001), 61-85.
81. C. Zhou, H.J. Zhou, X.F. Zhang, L.L. Lou, Q.H. Ye, Y. Zheng, J. Wang, H.T. Zhu, Q.Z. Dong, H.L. Jia, W.W. Zhu, L. Guo, Y. Zhao, D.M. Gao, L.X. Qin, Postoperative serum osteopontin level is a novel monitor for treatment response, and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma. Ann Surg Oncol 20 (2013), 929-937.